Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Rev Esp Enferm Dig ; 91(8): 541-8, 1999 Aug.
Artículo en Inglés, Español | MEDLINE | ID: mdl-10491486

RESUMEN

OBJECTIVE: primary gastric B-cell lymphoma of the mucosa-associated lymphoid tissue type has been linked to infection of the gastric mucosa with Helicobacter pylori. The eradication of this pathogen with antibiotics can lead to regression of this type of lymphoma. The objective of this study was to describe the clinical, endoscopic and histologic evolution in 6 patients with primary gastric B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with eradication of H. pylori. METHOD: descriptive study of a retrospective case series. Patients with low-grade gastric mucosa-associated lymphoid tissue type lymphoma were initially treated with eradication therapy for H. pylori. We evaluated their clinical, endoscopic and histologic course in sequential follow-up visits after initial therapy. RESULTS: six patients who satisfied all selection criteria were studied. In five of six patients H. pylori was eradicated and the lymphoma showed regression within 6 to 24 months. In one patient transition of low-grade to high-grade gastric lymphoma occurred. CONCLUSIONS: these results, along with similar findings from other studies, suggest eradication of H. pylori should be the initial treatment of choice for low-grade B-cell gastric mucosa-associated lymphoid tissue type lymphoma in the early stages. The most appropriate duration of follow-up is unknown, but prolonged follow-up is indicated to detect recurrences.


Asunto(s)
Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Linfoma de Células B de la Zona Marginal/terapia , Neoplasias Gástricas/terapia , Adulto , Anciano , Antibacterianos/uso terapéutico , Femenino , Gastroscopía , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/patología , Humanos , Linfoma de Células B de la Zona Marginal/microbiología , Linfoma de Células B de la Zona Marginal/patología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Neoplasias Gástricas/microbiología , Neoplasias Gástricas/patología
2.
Gastroenterol Hepatol ; 25(6): 383-6, 2002.
Artículo en Español | MEDLINE | ID: mdl-12069699

RESUMEN

AIMS: To evaluate the efficacy of 3-day intravenous Helicobacter pylori eradication therapy in patients with bleeding peptic ulcer associated with H. pylori infection. MATERIAL AND METHOD: We studied 53 patients admitted to hospital with bleeding of the upper gastrointestinal tract due to peptic ulcer and positive urease test over a 12-month period. After endoscopic diagnosis, intravenous pantoprazole (40 mg/12 hours), metronidazole (500 mg/8 hours) and amoxicillin-clavulanic acid (1,000 mg/200 mg/8 hours) was administered for 72 hours. The efficacy of eradication therapy was evaluated by 13C-urea breath test at least 2 months after the end of treatment. RESULTS: Fifty-one patients were included. Of these, 40 had duodenal ulcer and 11 had gastric ulcer. H. pylori eradication was achieved in 87.5% of those with duodenal ulcers and in 63.6% of those with gastric ulcers (p = 0.066). No adverse reactions or episodes of bleeding recurrence were found and none of the patients withdrew from treatment. CONCLUSIONS: The ultra-short course eradication therapy used in this study is highly effective. Its efficacy is similar to that of oral treatment and it avoids certain problems such as adverse effects and adherence to treatment.


Asunto(s)
Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Úlcera Péptica Hemorrágica/complicaciones , 2-Piridinilmetilsulfinilbencimidazoles , Adulto , Anciano , Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Antibacterianos/administración & dosificación , Antiulcerosos/administración & dosificación , Bencimidazoles/administración & dosificación , Distribución de Chi-Cuadrado , Intervalos de Confianza , Interpretación Estadística de Datos , Quimioterapia Combinada/administración & dosificación , Úlcera Duodenal/complicaciones , Femenino , Infecciones por Helicobacter/complicaciones , Humanos , Infusiones Intravenosas , Masculino , Metronidazol/administración & dosificación , Persona de Mediana Edad , Omeprazol/análogos & derivados , Pantoprazol , Úlcera Péptica Hemorrágica/etiología , Úlcera Gástrica/complicaciones , Sulfóxidos/administración & dosificación , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda